{
    "id": "dbpedia_8250_1",
    "rank": 64,
    "data": {
        "url": "https://www.bsmo.be/bsmo-meeting-materials-archive/",
        "read_more_link": "",
        "language": "en",
        "title": "BSMO meeting materials",
        "top_image": "https://www.bsmo.be/wp-content/uploads/cropped-favicon-32x32.jpg",
        "meta_img": "https://www.bsmo.be/wp-content/uploads/cropped-favicon-32x32.jpg",
        "images": [
            "https://www.bsmo.be/wp-content/themes/bureauvet/images/logo.png",
            "https://www.bsmo.be/wp-content/themes/bureauvet/images/logo.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2022-02-17T12:32:49+00:00",
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "https://www.bsmo.be/wp-content/uploads/cropped-favicon-32x32.jpg",
        "meta_site_name": "BSMO",
        "canonical_link": "https://www.bsmo.be/bsmo-meeting-materials-archive/",
        "text": "Presentations Friday 14 February\n\n10:00 Breast cancer task force\n\nOptimal adjuvant endocrine treatment in premenopausal patients with HR+/HER2-negative breast cancer Insights from clinical trials – Francois Duhoux, UC Louvain\n\nNeoadjuvant treatment considerations in HER2-positive breast cancer: Insights from clinical trials – Evandro De Azambuja, Institut Jules Bordet\n\nGene expression profiling in early breast cancer in the context of the Belgian pilot project – Donatienne Taylor, CHU UCL NAMUR Sainte-Elisabeth\n\n13:30 Onco-geriatrics – Lore Decoster, UZ Brussel\n\n14:30 HCC – Ivan Borbath, UCL\n\n15:00 Cardio-oncology – Marie Moonen, CHU de Liege\n\n16:00 O.01 Surgical treatment of hepatic metastases from oligometastatic breast cancer: the histopathological growth pattern of liver metastases as a predictor of postoperative outcome – an emerging biomarker? – Emily Latacz, GZA Hospitals & University of Antwerp\n\n16:10 O.02 Relapsing and non-relapsing patients with luminal breast cancer exhibit differential plasma expression of several chemokines and microRNAs at diagnosis – Yentl Lambrechts, KU Leuven\n\n16:20 O.03 Immune cell infiltration in cervical tumor tissue as a marker for response to (chemo) radiotherapy – Lien Lippens, Ghent University\n\n16:30 O.04 Tumor sequencing is useful to reclassify germline variants in unexplained high-risk breast cancer families – Cédric Van Marcke, Cliniques universitaires Saint-Luc\n\n16:40 O.05 c-MET as a potential resistance mechanism to everolimus in breast cancer; from a case report to patient cohort analysis – Valentin Van den Bossche, UC Louvain\n\n16:50 O.06 The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: preliminary results of a randomized, placebo-controlled trial – Joy Lodewijckx, Hasselt University\n\n17:00 O.07 Prognostic value of TILs evaluation with a standardized method in oropharynxcarcinoma – Stijn De Keukeleire, UZ Gent\n\n17:10 O.08 Evaluating the impact of metformine on breast cancer aggressiveness and on chemotherapy efficacy: A retrospective and translational cohort analysis – Natasha Honoré, UCL, Woluwe Saint-Lambert\n\nPresentations Saturday 15 February"
    }
}